Cytodyn Inc (CYDY)

[ClosetInvestor]

“My initial thoughts:

1, Subgroup or not, why didn't these 3 lawyers acknowledge the amazing success of LL in reducing mortality after 7 and 14 days?”

News flash: there wasn’t an amazing success with the subgroups. A sub-group analysis from a failed trial is flawed from the onset. Per the FDA, there were sub-groups who favored placebo and others who favored leronlimab and none were statically significant.

“Here, the data from CD12 illustrated imbalances in mortality among subgroups, some favoring leronlimab and some favoring placebo. None of these analyses met statistical significance when using established and reliable analytical methods that correct for multiple comparisons.”